News

DiscoveryBioMed, Inc. Is Proving to Be an Advantageous CRO for Artificial Intelligence (AI) Firms Focused on Drug Target and Discovery for Human Genetic Diseases and Human Diseases in General

DiscoveryBioMed, Inc. is a niche CRO that specializes in the creation and use of diseased and normal human cell platforms in 'off the shelf' and customized in vitro bioassays.  Our services are particularly useful to recently established and emerging artificial intelligence firms focused on identifying new drug targets for human diseases and candidate small molecules that may be purposed and/or re-purposed for human diseases. Critically, the output of these AI processes needs to be tested in living, intact human cell platform technologies to (1) validate the AI-driven output and (2) optimize and refine the drug targets and candidate drugs in vitro in human cell platforms and assays of biological relevance and disease relevance before embarking on more expensive in vivo animal model studies and in vivo animal toxicology studies.  Please reach out to DBM on our website, www.discoverybiomed.com, and inquire via our CRO services inquiry portals located in many places on our webpages. We can follow up with a 'white paper' that summarizes our existing 'off the shelf' capacity and capabilities as well as introduce new human cell platforms and...

Read More

The Sage Group Is Representing DiscoveryBioMed, Inc. Actively in M&A Partnering

DiscoveryBioMed, Inc. (DBM) is excited to announce that The Sage Group is actively representing the company and our multiple assets in M&A partnering conversations. “We met Bill Mason, Wayne Pambianchi, and other principals for The Sage Group in BIO Digital, the 2020 virtual partnering event. They have deep experience in the life sciences and biotechnology sector and principals covering virtually every continent and market”, explained Dr. Erik Schwiebert, DBM’s Founder and Director. “DBM has completed 12 years of business and we are currently in our 13th year. Our CRO services business is growing and has a positive trajectory, we have multiple and different preclinical lead small molecule assets with a focus in the Human Renal Diseases landscape, and we have identified a unique niche in discovering, validating and/or profiling new small molecules or existing lead therapeutic assets in disease-relevant and biologically-relevant human cells from a plethora of different human tissues.” The Sage Group has Information Memoranda for both sides of the DBM business and they will be representing DBM at BIO Europe at the end...

Read More

A heartfelt Thank You and a Special Offer for our Global CRO Services Clients

DiscoveryBioMed, Inc. (DBM)has remained in business using a lab shift-based model and extra precautions through the entirety of this global health crisis since March 2020 and we continue to follow strict guidelines. We wanted to extend a quite heartfelt thank you to all of our CRO services clients which is growing and global clientele from across the US, Canada, multiple parts of the UK, multiple parts of the European Union, and Japan. Your continued patronage is very important to us, and the applied science we are doing to profile lead therapeutic assets for different human diseases and to screen for new ligands for different applied science indications is continually rewarding, fun and interesting We have added two new units during 2020. Our Sentirix unit is focused on the applied science use of human taste cell platforms for multiple industry sectors. Our TumorCube unit is focused on niche forms of human cancer where the cells are cultured and profiled as 3D organoid tissues as well as in traditional 2D formats. We continue deep efforts in our...

Read More

DiscoveryBioMed, Inc. Involved Actively in BIO Alabama Annual Conference, October 5-8

DiscoveryBioMed, Inc. (DBM) is honored and excited to be involved in the BIO Alabama Annual Conference to be held virtually from October 5-8. There are some great keynote speakers and sessions as well as a one-on-one partnering vehicle that DBM is co-sponsoring for the event. “At the BIO International Convention, DBM takes full advantage of the One on One Partnering vehicle to connect to future potential partners and clients,” explained Dr. Erik Schwiebert, CEO and CSO of DBM. “We encouraged a similar vehicle, given the virtual format for the meeting, where connections can be made and/or deepened across the BIO Alabama network and ecosystem.” In addition, Erik is joining Rachel Lane that leads a scientific writing enterprise called The Written Science for a fireside chat on small business grant programs at the NIH and NSF for life sciences and biotechnology companies. Erik is also going to connect virtually to the Auburn Engineering Club one evening that week to discuss the life sciences and biotechnology career path, DBM, and other topics of interest to Auburn undergraduates....

Read More

BIO ALABAMA-FIRESIDE CHAT WITH DR. ERIK SCHWIEBERT

We are pleased to announce our CEO and Chief Scientific Officer, Dr. Erik Schwiebert, will provide his expert insight into NIH vs NSF SBIR-STTR Programs in a Fireside Chat as part of this year’s BIO Alabama virtual conference. BIO Alabama is the leading advocate for Alabama's bioscience community. As the State affiliate of Biotechnology Innovation Organization, BIO Alabama represents the State regionally, nationally, and internationally by promoting the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. This annual conference will include over 20 sessions and 40 speakers! Registration is open and we hope you will consider joining our annual conference. You can view the entire agenda and speaker roster here. We look forward to connecting with you virtually soon! Registration is open and we hope you will consider joining our annual conference.

Read More

TumorCube, a New Unit within DiscoveryBioMed, Will Use 3D Biogel-based Platforms to Perform 384-Well Plate-based Bioassays and 3D Bioreactor-driven Studies to Discover, Validate and Profile Anti-cancer Therapeutics on Human Cancer Cells

DiscoveryBioMed, Inc. (DBM, www.discoverybiomed.com) announces a new unit of its contract research organization (CRO) services business called TumorCube that is formed based upon our growing expertise in 3D Biogel-driven bioassays on diseased and normal human cell platform technologies. A trademark application has been filed. "DBM has a growing CRO services business in 3D Biogel-driven bioassays of diseased and normal human kidney cells. It is showcased prominently on our website, and we are proud to have many biotechnology companies and BioPharmaceutical organizations globally as our clients," explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. "We have now extended those offerings to include the assay of human urological cancers and endocrine-driven cancers such as ovarian cancers and breast cancers." DBM is also assessing the feasibility of our 3D platforms for the assay of neurological and other cancers at present. DBM is utilizing existing human cancer cell lines in our initial technology optimization. "Interestingly, diseased human kidney cells and existing human cancer cell lines respond differently to specific lead therapeutic drugs or industry standard anti-cancer drugs when grown in...

Read More